Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive

Krista Laine1, Kristiina Järvinen, Tomi Järvinen

  • 1Department of Pharmaceutical Chemistry, University of Kuopio, POB 1627, Finland. krista.laine@uku.fi

Life Sciences
|December 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-group simulation as a remote learning method in interprofessional health care education - a mixed methods study.

Nurse education today·2025
Same author

Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.

International journal of pharmaceutics·2018
Same author

Human corneal cell culture models for drug toxicity studies.

Drug delivery and translational research·2016
Same author

Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2015
Same author

Novel delivery systems for improving the clinical use of peptides.

Pharmacological reviews·2015
Same author

Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib.

Biomaterials·2015

Cannabinoid receptor type 2 (CB2) agonists, like JWH-133, did not lower intraocular pressure (IOP) in rabbits. This suggests CB2 agonists may not be effective for glaucoma treatment, unlike CB1 receptor agonists.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Neuroscience

Background:

  • Cannabinoid effects on intraocular pressure (IOP) are primarily linked to CB1 receptors.
  • The role of CB2 receptors in regulating IOP remains largely unexplored.

Purpose of the Study:

  • To investigate the IOP-lowering potential of the selective CB2 receptor agonist JWH-133 in normotensive rabbits.
  • To compare the effects of JWH-133 with CP55,940, a known cannabinoid receptor agonist.

Main Methods:

  • Ocular administration of JWH-133 and CP55,940 in various formulations (HP-beta-CD, propylene glycol) to rabbit eyes.
  • Measurement of intraocular pressure (IOP) at regular intervals post-administration.

Main Results:

  • JWH-133, at tested doses and formulations, showed no significant effect on IOP compared to vehicle controls.

Related Experiment Videos

  • CP55,940 demonstrated significant IOP reduction in both HP-beta-CD and propylene glycol formulations.

    • Conclusions:

    • Topical application of the CB2 agonist JWH-133 does not lower IOP in normotensive rabbits.
    • CB2 receptor agonists may not represent a viable therapeutic strategy for reducing IOP in conditions like glaucoma.